Aiforia as an investment

Aiforia as an investment

Pathology is going digital, and laboratories increasingly need solutions that streamline diagnostic workflows and improve precision. Aiforia is well-positioned to lead the shift to AI-driven precision diagnostics.

The challenge: More cases, more complexity, fewer pathologists

Pathologists play a central role in healthcare: they examine and diagnose patient samples to guide medical treatment. But aging populations and rising disease rates are putting unprecedented strain on healthcare systems worldwide. Annual global cancer incidence is projected to rise by 77%, from 20 million cases in 2022 to over 35 million by 2050. This is driven largely by demographic change, as the share of the world’s population aged 65 and older grows from 9.3% in 2020 to 16.0% in 2050.

Each case is also becoming more demanding. Between 2006 and 2014, the number of slides per pathology case rose by 60%, as laboratories took more tissue biopsies and more slides per biopsy. Over the same period, immunohistochemistry slides per case nearly doubled and molecular testing more than tripled, driven by precision-medicine diagnostics.

This adds a heavy burden to a workforce that is already stretched. The US alone faces a projected shortage of 3,520 full-time equivalent (FTE) pathologists by 2038. In the UK, 47% of pathologists are expected to retire within 10 years. Legacy tools widen the gap: manual slide analysis with traditional microscopes is slow, labor-intensive, and prone to variability.

Our solution: AI-assisted analysis

AI can help healthcare systems meet these challenges. AI-driven workflow makes sample review more consistent and less subjective, while improving speed and accuracy. It supports pathologists in their work and enables precision diagnostics. This can help patients get diagnoses faster, enable more personalized treatment, and widen access to expert diagnostics.

Sources: WHO/IARC GLOBOCAN 2022 (published 2024), HRSA, Physician Workforce: Projections, 2023–2038 (2025), RCPath Workforce Census, 2025, Warth et al., Virchows Arch 2016

Why invest in Aiforia?

Global momentum

Aging populations and rising rates of diseases such as cancer are increasing the pressure on healthcare systems worldwide. Pathologists face more and more complex cases, and they need better ways to analyze samples to keep up. Expansion in digital pathology is widespread, as the adoption of microscope scanners to convert samples into digital images is increasing, making it possible for laboratories to adopt AI. Global pathology slides digitalization rate 2029 is estimated to reach 51% (Customized Global Microscope Slide Industry Market Research Report 2024)

The pharmaceutical industry is speeding up the shift to precision diagnostics. A growing share of new cancer therapies are targeted treatments that work only for patients with specific biomarkers, so the decision to treat depends on accurate tissue testing. Pharmaceutical companies increasingly use digital pathology and AI in drug development and clinical trials to measure these biomarkers consistently, and to develop the companion diagnostics that bring new therapies to patients. As these therapies reach the market, the need for precise, reproducible biomarker analysis moves from research into routine clinical diagnostics.

One platform for research and clinical use

Aiforia has offered commercial tools for training AI models since 2018, enabling healthcare professionals to create and deploy their own image analysis models. One unified platform supports the whole workflow, from discovery and preclinical research to diagnostic and prognostic clinical use. This approach, together with continuous product development leveraging advanced technologies such as foundation models, has driven adoption worldwide among major pharma and biotech companies, leading academic research institutes, and clinical pathology laboratories.

A scalable business model

Aiforia’s revenue comes from recurring, high-margin software use by healthcare customers who tend to stay for the long term, which gives the business strong potential to scale and become profitable.

Aiforia’s growth is driven by the market’s broadest portfolio of CE-IVD-marked AI models in pathology, complemented by custom AI models that customers build themselves. The platform integrates with laboratories’ existing systems, as several live deployments show, and strategic partnerships extend its reach. Together, these enable Aiforia to deliver complete solutions that fit into customers’ workflows. Direct and partner sales serve both preclinical and clinical customers.

Business model

Read more about our business model

Management team

Read about our management team